Many cytotoxic cancer drugs depend on BAX/BAK-dependent mechanisms to facilitate their anti-tumor effects, and upregulation of BCL-2 anti-apoptotic proteins facilitates resistance to several chemotherapies (Fig. 2) [36, 37, 39–41]. Here, BCL2 is linked to neoplasm.